Teja Kulkarni

The “why” behind every decision is the person in front of us. In this conversation, I joined the Leap Together podcast to discuss the real-world complexity for patients living with pulmonary fibrosis.

Listen here: lpcur.com/LeapTogether... 

#LeapTogetherPodcast #ClinicalTrials #curePF

Screen shot of title page

The Impact of Pulmonary Fibrosis on Sex and Sexual Function - A Multinational Mixed Methods Study

Just out in ERJ and led by Dr. Na'ama Avitzur
A 🧵👇
(key take-away 👉 sex matters to patients with PF and their disease impacts this)

#OpenAccess #CurePF #CureIPF
publications.ersnet.org/content/erj/...

The approval of Nerandomilast marks a pivotal step forward in IPF care. For patients living with IPF, this offers long awaited hope and this milestone underscores the collective efforts of multiple stakeholders who never stopped pushing for better therapeutic options for IPF.

FDA approves drug to treat idiopathic pulmonary fibrosis First new treatment in more than a decade for rare lung condition

Yesterday, the U.S. FDA approved Jascayd (nerandomilast) to treat IPF. This is the first IPF new therapy approved in more than a decade.
Congratulations to all our patients & yes, better drugs are on the way!!
Great day for the #CureIPF community!!
#ScienceMatters
www.fda.gov/drugs/news-e...

Text of primary and secondary endpoints

TETON-2 phase 2 RCT of nebulized treprostinil for IPF 🫁

Positive trial 🗞️
Change in FVC at 52 weeks difference of 95.6mL (!), and 2* endpoints like K-BILD

@ipfdoc.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social

www.theglobeandmail.com/investing/ma...

Heading to #ATS2025 🫁?
Wondering about the Clinical Problems assembly content?
📻 Check out this podcast where we break it down for you 👇😁

@ats-clinicalprobs.bsky.social
@atsearlycareer.bsky.social

Perspectives of people living with idiopathic pulmonary fibrosis: a qualitative and quantitative study - BMC Pulmonary Medicine Background The antifibrotic therapies, pirfenidone and nintedanib, have been approved since 2014 for idiopathic pulmonary fibrosis (IPF), but in the United States only a quarter of people living with ...

Amplification of patients voices is key to personalized care. Excited about our recent study highlighting the disease burden and critical gaps as we move towards patient focused management for individuals living with IPF #curePF bmcpulmmed.biomedcentral.com/articles/10....

Had the same question when I saw this paper- typically co-manage SSc patients with our rheumatology colleagues and ILD team are predominant prescribers for Nintedanib.

Fibrosis: cross-organ biology and pathways to development of innovative drugs - Nature Reviews Drug Discovery Fibrosis is a key characteristic of a range of chronic diseases that has been challenging to target with drugs. This Review highlights core pathways active in fibrotic conditions across organs, as wel...

Informative piece in @naturerevdrugdisc.bsky.social on cross-organ fibrosis and informing drug development. @ipfdoc.bsky.social @gilliangoobie.bsky.social @kerrijohannson.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @drdayjee.bsky.social
www.nature.com/articles/s41...

Exactly. Think about it - what if this drug improves FVC - what would the patients’ risk tolerance be?

Hope so! Especially since there seems to be an efficacy signal.

American Thoracic Society | ATS Apprenticeship Program The American Thoracic Society is the world's leading medical society dedicated to accelerating the advancement of global respiratory health through…

The ATS CP apprenticeship program is a great way to get involved with the assembly!

Get more info and apply here:
tinyurl.com/439v6xam

Make sure to select the clinical problems assembly and apply before January 24!⏰

#pulmsky #medsky

Screenshot of the article title and authors

🌟 Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease 🌟

Just out in @atsblueeditor.bsky.social 🫁

www.atsjournals.org/doi/abs/10.1...

State of the Art:
-Epidemiology
-Mechanisms of Injury
-Implications - clinical & policy
-Future directions

Happy New Year!

Please add me too! #CurePF

screenshot of study title. Effects of nintedanib on biomarkers in IPF in ERJ Open.

Now can we use CA-125 as a theragnostic biomarker of treatment response in patients with IPF? Why wouldn't we?

@ipfdoc.bsky.social @kaminskimed.bsky.social
#CurePF #CureIPF @ats-clinicalprobs.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social

pmc.ncbi.nlm.nih.gov/articles/pmi...

An excellent 🧵on potential application of Mendelian randomization towards target identification and therapeutic development #cureIPF #REMAP-ILD

There’s still time to submit session ideas for #CHEST2025! Don't miss your chance to speak! Need help? Just ask me! info.chestnet.org/chest-call-f...

👆I feel like if it is used responsibly to aid with language (and not the underlying science), there might be precedence to allow it- wouldn’t it be easy to implement this though.

🙋‍♀️

👋 I'm a pulmonary critical care physician and ILD specialist at UAB. Within ATS, I'm active in the Clinical Problems Assembly!

Among other factors, this real-world study underscores the importance of addressing mental health in patients with IPF #curePF

Continued awareness and identification of IPF needs to continue.

🙋‍♀️

So excited to hear what @kerrijohannson.bsky.social has to tell us about the impact of our environment on the development of pulmonary fibrosis! The whole lecture will be available on-line via the MTW website: www.imperial.ac.uk/mtw-centre-f...

Cover of AJRCCM

Really cool! our “Single-Cell Analysis Reveals Novel Immune Perturbations in Fibrotic Hypersensitivity Pneumonitis” made it to cover of the American Journal of Respiratory & Critical Care Medicine. Kudos to soon to be #DoubleDoc Amy Zhao & crew!! #BestStudents www.atsjournals.org/doi/full/10....

Made my first pilgrimage to ACCP in Glenview, IL this week. Thanks #Chest for the hospitality! @tkulkarni.bsky.social